CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,905 enrolled
Drug / intervention
Percutaneous Coronary Intervention +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01205776
NCT01205776N/ACompleted
CompareCT.gov

Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization.

Abbott Medical Devices·interventional·Posted Sep 20, 2010·Updated Apr 7, 2020

In Brief

A clinical study evaluating Percutaneous Coronary Intervention and CABG for Chronic Coronary Occlusion and 8 related conditions. Completed, enrolled 1,905 participants across 1 site.

Detailed Summary

To establish the safety and efficacy of the commercially approved XIENCE Family Stent System (inclusive of XIENCE PRIME, XIENCE V, XIENCE Xpedition and XIENCE PRO \[for use outside the United States \[OUS\] only\]) in subjects with unprotected left main coronary artery disease by comparing to coronary artery bypass graft surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 20, 2010
Enrollment StartSep 29, 2010
Primary CompletionMay 3, 2019
Study CompletionJun 28, 2019
TodayJul 2, 2026
Enrollment to primary: 8.6 yearsPosted 15.8 years ago

Interventions

Percutaneous Coronary Interventiondevice

Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS

CABGprocedure

Those patients receiving CABG